Methotrexate subcutaneous auto-injection - Antares Pharma

Drug Profile

Methotrexate subcutaneous auto-injection - Antares Pharma

Alternative Names: Otrexup; VIBEX MTX

Latest Information Update: 01 Apr 2016

Price : $50

At a glance

  • Originator Antares Pharma
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 01 Apr 2016 The US FDA approves interim dosage strengths of methotrexate for treatment of Rheumatoid arthritis, Juvenile rheumatoid arthritis and Psoriasis in USA
  • 07 Sep 2015 Antares Pharma terminates its licence for Methotrexate auto-injection in USA
  • 27 Apr 2015 LEO Pharma terminates its license for methotrexate in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top